BoobyBiome’s innovative probiotic supplement, informed by breast milk microbiome research, represents a significant leap forward in promoting infant wellbeing.

CPI collaborated with BoobyBiome to optimise bacterial growth conditions and establish scalable methods for producing the supplement. This groundbreaking solution holds immense promise for infant health and has now been shown to be both scalable and manufacturable, accelerating this product to supermarkets and hospitals in the near future.

Easily added to formula or breast milk, the supplement will boost the gut health of newborn babies. By supporting early immune system development, through a robust gut microbiome, the supplement will provide both short and long-term health benefits throughout infancy and childhood.

Our work with BoobyBiome will be key to making the supplement commercially viable so that it can reach the babies that need it the most. It will also pave the way for more research in this important and under-studied area. By enabling the success of this unique and necessary product, we can help give infants and our future generations a better start in life, one tiny gut microbiome at a time.